ZA200609337B - Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin - Google Patents

Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin

Info

Publication number
ZA200609337B
ZA200609337B ZA200609337A ZA200609337A ZA200609337B ZA 200609337 B ZA200609337 B ZA 200609337B ZA 200609337 A ZA200609337 A ZA 200609337A ZA 200609337 A ZA200609337 A ZA 200609337A ZA 200609337 B ZA200609337 B ZA 200609337B
Authority
ZA
South Africa
Prior art keywords
prevention
treatment
diseases associated
opioid antagonist
antagonist compounds
Prior art date
Application number
ZA200609337A
Other languages
English (en)
Inventor
Schmidhammer Helmut
Original Assignee
Alcasynn Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcasynn Pharmaceuticals Gmbh filed Critical Alcasynn Pharmaceuticals Gmbh
Publication of ZA200609337B publication Critical patent/ZA200609337B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200609337A 2004-05-12 2006-11-09 Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin ZA200609337B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04011293A EP1595541A1 (fr) 2004-05-12 2004-05-12 Utilisation d'antagonistes aux récepteurs opioides pour prévenir et/ou traiter les maladies associées à la cible calcineurine

Publications (1)

Publication Number Publication Date
ZA200609337B true ZA200609337B (en) 2008-08-27

Family

ID=34924978

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200609337A ZA200609337B (en) 2004-05-12 2006-11-09 Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin

Country Status (14)

Country Link
US (1) US20070167474A1 (fr)
EP (2) EP1595541A1 (fr)
JP (2) JP2007537198A (fr)
CN (1) CN1997369B (fr)
AT (1) ATE445401T1 (fr)
AU (1) AU2005239831A1 (fr)
CA (1) CA2566398A1 (fr)
DE (1) DE602005017145D1 (fr)
ES (1) ES2334042T3 (fr)
MX (1) MXPA06013128A (fr)
NO (1) NO20065551L (fr)
RU (1) RU2006143770A (fr)
WO (1) WO2005107752A2 (fr)
ZA (1) ZA200609337B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009122436A2 (fr) 2008-03-31 2009-10-08 Sun Pharmaceutical Industries Ltd. Procédé perfectionné pour la préparation d'analogues de morphinane
WO2009132313A2 (fr) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Dérivés de morphinane d’acides organiques et inorganiques
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP2641588B1 (fr) * 2012-03-23 2017-11-22 Induchem Holding AG Utilisation d'agonistes du récepteur opioïde delta dans le domaine cosmétique et dermocosmétique
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
EP3197346B1 (fr) * 2014-09-22 2020-02-26 National Health Research Institutes Utilisation de 5-méthoxytryptophane comme agent de diagnostic de maladies inflammatoires
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1043766C (zh) 1992-09-29 1999-06-23 东丽株式会社 吲哚衍生物及其制法和它们在制备药物中的应用
SE9401728D0 (sv) * 1994-05-18 1994-05-18 Astra Ab New compounds II
KR20030060771A (ko) * 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 국소용 마취제/아편양약물 제제 및 이들의 용도
AU2002227135B2 (en) 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
CA2498046A1 (fr) 2002-09-18 2004-04-01 The Curators Of The University Of Missouri Analogues d'opiaces selectifs a l'egard du recepteur opioide delta

Also Published As

Publication number Publication date
EP1595541A1 (fr) 2005-11-16
JP2007537198A (ja) 2007-12-20
ES2334042T3 (es) 2010-03-04
RU2006143770A (ru) 2008-06-20
DE602005017145D1 (de) 2009-11-26
AU2005239831A1 (en) 2005-11-17
WO2005107752A2 (fr) 2005-11-17
US20070167474A1 (en) 2007-07-19
CN1997369B (zh) 2011-12-21
WO2005107752A3 (fr) 2006-06-01
MXPA06013128A (es) 2007-04-27
CN1997369A (zh) 2007-07-11
CA2566398A1 (fr) 2005-11-17
EP1755604B1 (fr) 2009-10-14
JP2012254986A (ja) 2012-12-27
NO20065551L (no) 2007-02-05
ATE445401T1 (de) 2009-10-15
EP1755604A2 (fr) 2007-02-28

Similar Documents

Publication Publication Date Title
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
BR0312934A (pt) Derivados de 8-hidróxi quinolina
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
GEP20125405B (en) Amino-heterocyclic compounds
WO2005023759A3 (fr) Inhibiteurs heterocycliques de mek et procedes d'utilisation associes
WO2005089753A3 (fr) Benzisoxazoles
ATE517882T1 (de) Chinolinderivate
TW200607807A (en) Macrocyclic beta-secretase inhibitors
EP2650293A8 (fr) Composé de [1,2,4]triazolo[4,3-b][1,2,4]triazine, son procédé de préparation et son utilisation
PT2385053E (pt) Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
MY147442A (en) Imidazoquinolines as lipid kinase inhibitors
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
WO2010045251A3 (fr) Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
NZ593440A (en) Aminopyrazole compounds useful for inhibiting chk1
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2007092157A9 (fr) 7-[1h-imidazol-4-yl) methyl]-5,6,7,8-tetrahydroquinoline
ZA200609337B (en) Use of opioid antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
WO2008004100A9 (fr) Composés thérapeutiques
TW200732304A (en) Piperidine derivatives
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents